APP and Parkinson disease: Met alleviated inflammation in the DM+PD group by mitigating serum levels of pro-inflammatory TNF-α and anti-inflammatory IL-10, which is consistent with other research that shown Met enhancing memory and learning in APP/PS1 through improved neurogenesis and decreased inflammation (Ou et al. 2018; Saffari et al. 2020).